肝细胞来源细胞外囊泡通过miR-153-3p-焦亡轴促进慢性肝病内皮细胞去分化
研究探讨肝细胞来源细胞外囊泡(hepEVs)中microRNA在慢性肝病中对肝窦内皮细胞(LSECs)去分化的调控作用。从人和大鼠健康及肝硬化肝脏分离hepEVs,发现肝硬化hepEVs富集miR-153-3p,可触发LSECs焦亡并导致内皮功能障碍;抑制Caspase-1可改善内皮表型及门脉高压。
要点
- 肝硬化肝细胞来源EVs主要蓄积于LSECs并破坏纤维化、炎症及细胞死亡相关基因。
- miR-153-3p经hepEVs旁分泌进入LSECs,诱导焦亡相关基因失调及Caspase-1/GSDMD活化。
- Caspase-1抑制剂VX-765可减轻肝脏焦亡、改善内皮表型及门脉高压。
核心结论
- hepEVs来源的miR-153-3p通过旁分泌机制触发LSECs焦亡,参与慢性肝病内皮功能障碍。
- 抑制Caspase-1可能为减轻慢性肝病内皮功能障碍提供新治疗途径。
研究设计与样本
- 从人和大鼠健康(CT)及肝硬化(CH)肝脏分离原代肝细胞并纯化EVs。
- CT大鼠静脉注射荧光标记hepEVs-CT或hepEVs-CH(200 μg/d,3 d,n=10/组)评估生物分布及LSECs表型。
- 对人hepEVs-CH进行miRNA谱分析并在大鼠模型中验证,将共同改变的miRNA过表达于CT-LSECs。
- CH大鼠接受Caspase-1抑制剂VX-765(15 mg/kg/d,10次,n=11/组)治疗,评估肝功能、血流动力学及内皮表型。
主要发现
- 体内hepEVs-CH主要蓄积于LSECs,破坏纤维化、炎症和细胞死亡相关基因,增强von Willebrand因子表达并改变eNOS活性。
- 人hepEVs-CH中37个miRNA失调,miR-200a-3p和miR-153-3p在大鼠hepEVs-CH中得到验证。
- miR-153-3p转染CT-LSECs导致771个炎症和细胞死亡相关基因失调,尤其焦亡通路。
- 人和大鼠肝硬化肝组织及经miR-153-3p-hepEVs处理的CT-LSECs中活性Caspase-1和Gasdermin-D表达增加。
- VX-765治疗减少肝脏焦亡,改善内皮表型和门脉高压。
临床怎么用
- hepEVs中的miR-153-3p可作为慢性肝病内皮功能障碍的潜在生物标志物或干预靶点。
- Caspase-1抑制可能成为改善肝硬化门脉高压及内皮功能障碍的治疗策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Liver cells communicate paracrinally through extracellular vesicles (EVs). This study investigated the role of microRNAs (miRNAs) embedded in hepatocyte-derived EVs (hepEVs) modulating endothelial cell dedifferentiation in chronic liver disease. APPROACH AND RESULTS: EVs were purified from primary hepatocytes isolated from healthy (CT) and cirrhotic (CH) livers in both humans and rats. CT-rats were intravenously treated with fluorescence-labeled hepEVs-CT or hepEVs-CH (200 μg/d, 3 d, n=10/group) to assess biodistribution and LSECs phenotype. miRNA profiling of human hepEVs-CH was validated in rat models, and commonly altered miRNAs were overexpressed in CT-LSECs. Gene dysregulation was analyzed in primary CH-LSECs and liver tissues from rats and humans with cirrhosis, as well as CT-LSECs treated with miRNA-specific upregulated hepEVs. CH-rats were treated with the Caspase-1 inhibitor VX-765 (15 mg/kg/d, 10 doses, n=11/group) to evaluate its effects on liver function, hemodynamics, and endothelial phenotype. In vivo, hepEVs-CH accumulated predominantly in LSECs, disrupting genes involved in fibrosis, inflammation, and cell death, while enhancing the von Willebrand factor expression and altering eNOS activity. Profiling of human hepEVs-CH revealed 37 dysregulated miRNAs, with miR-200a-3p and miR-153-3p validated in rat hepEVs-CH. Transfection of miR-153-3p into CT-LSEC dysregulated 771 genes involved in inflammation and cell death, particularly pyroptosis. Increased active Caspase-1 and Gasdermin-D expression was observed in human and rat cirrhotic liver tissue, as well as in CT-LSEC treated with miR-153-3p-hepEVs, indicating enhanced pyroptosis. In vivo, VX-765 treatment reduced hepatic pyroptosis, improving endothelial phenotype and portal hypertension. CONCLUSIONS: HepEVs-derived miRNAs, particularly miR-153-3p, contribute to endothelial dysfunction in chronic liver disease by triggering pyroptosis through a paracrine mechanism. Inhibiting Caspase-1 may provide a novel therapeutic approach to mitigate endothelial dysfunction in chronic liver disease.
引用
- Abad-Jordà L, Andrés-Rozas M, Martínez-Alcocer A, et al. Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p-pyroptosis axis. Hepatology. 2025. PMID: 41072000. doi:10.1097/HEP.0000000000001567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。